

## 1. Company details

Name of entity:	Prescient Therapeutics Limited
ABN:	56 006 569 106
Reporting period:	The half-year ended 31 December 2025
Previous period:	The half-year ended 31 December 2024

## 2. Results for announcement to the market

				\$
Revenues from ordinary activities	↓	98.1%	to	3,712
Loss from ordinary activities after tax attributable to the owners of Prescient Therapeutics Limited	↑	62.8%	to	(3,986,793)
Loss for the half-year attributable to the owners of Prescient Therapeutics Limited	↑	62.8%	to	(3,986,793)

### Dividends

There were no dividends paid, recommended or declared during the current financial period.

### Comments

The loss for the consolidated entity after providing for income tax amounted to \$3,986,793 (31 December 2024: \$2,449,088).

### Financial performance

The consolidated entity recognised an estimated R&D Tax Incentive rebate of \$1,147,776 (31 December 2024: \$1,248,426) relating to eligible R&D expenditure of \$2,482,204 (31 December 2024: \$1,706,161).

Operating expenses increased to \$5,148,281 (31 December 2024: \$3,891,968), primarily due to higher clinical trial and development activity for PTX-100 and increased share-based payment expenses following the issue of option awards during the half-year.

### Financial position

Net assets increased to \$16,971,592 (30 June 2025: \$11,387,172), largely driven by a combined capital raise of \$9,847,790 (before costs) from a Placement and Share Purchase Plan completed during the half-year.

Other key movements included an increase in the R&D Tax Incentive receivable to \$5,504,173 and a reduction in trade and other payables. The R&D Tax Incentive receivable amount of \$4,356,397 at 30 June 2025 was received on 21 January 2026.

## 3. Net tangible assets

	Reporting period Cents	Previous period Cents
Net tangible assets per ordinary security	<u>1.46</u>	<u>1.21</u>

## 4. Control gained over entities

Not applicable.

## 5. Loss of control over entities

Not applicable.

## 6. Dividends

### *Current period*

There were no dividends paid, recommended or declared during the current financial period.

### *Previous period*

There were no dividends paid, recommended or declared during the previous financial period.

---

## 7. Dividend reinvestment plans

Not applicable.

---

## 8. Details of associates and joint venture entities

Not applicable.

---

## 9. Foreign entities

### *Details of origin of accounting standards used in compiling the report:*

Not applicable.

---

## 10. Audit qualification or review

### *Details of audit/review dispute or qualification (if any):*

The financial statements were subject to a review by the auditors and the review report is attached as part of the Interim Report.

---

## 11. Attachments

### *Details of attachments (if any):*

The Interim Report of Prescient Therapeutics Limited for the half-year ended 31 December 2025 is attached.

---

## 12. Signed



Signed \_\_\_\_\_

Date: 24 February 2026

Dr James Campbell  
Non-Executive Chairman


For personal use only

# Prescient Therapeutics Limited

ABN 56 006 569 106

Interim Report - 31 December 2025

For personal use only



Corporate directory	4
Directors' report	5
Auditor's independence declaration	7
Consolidated statement of profit or loss and other comprehensive income	8
Consolidated statement of financial position	9
Consolidated statement of changes in equity	10
Consolidated statement of cash flows	11
Notes to the consolidated financial statements	12
Directors' declaration	17
Independent auditor's review report to the members of Prescient Therapeutics Limited	18

For personal use only

Directors	Dr James Campbell (Non-Executive Chairman) Dr Allen Ebens (Non-Executive Director) Dr Ellen Feigal (Non-Executive Director) Dr Gavin Shepherd (Non-Executive Director) Ms Melanie Farris (Non-Executive Director)
Company secretary	Ms Melanie Leydin
Registered office	Suite 2, Level 11, 385 Bourke Street Melbourne, VIC 3000 Phone: 03 9692 7222
Principal place of business	Suite 2, Level 11, 385 Bourke Street Melbourne, VIC, 3000
Share register	Automic Registry Services Level 5 126 Phillip Street Sydney NSW 2000 Phone: 02 9698 5414
Auditor	William Buck Level 20, 181 William Street Melbourne VIC 3000
Stock exchange listing	Prescient Therapeutics Limited securities are listed on the Australian Securities Exchange (ASX code: PTX)
Website	<a href="https://ptxtherapeutics.com">https://ptxtherapeutics.com</a>

For personal use only

The Directors present their report, together with the financial statements, for Prescient Therapeutics Limited ("Prescient" or "the Company") and its controlled entities ("the consolidated entity") for the half-year ended 31 December 2025.

### **Directors**

The following persons were Directors of Prescient Therapeutics Limited during the whole of the half-year and up to the date of this Report:

Dr James Campbell (Non-Executive Chairman)  
Dr Allen Ebens (Non-Executive Director)  
Ms Melanie Farris (Non-Executive Director)  
Dr Ellen Feigal (Non-Executive Director)  
Dr Gavin Shepherd (Non-Executive Director)

### **Principal activities**

During the half-year, the principal activities of the consolidated entity were:

- Conducting clinical studies and other research and development relating to the Company's proprietary technologies and products, including PTX-100;
- Business development activities to support the promotion and partnering of Prescient's proprietary technologies and products.

### **Review of operations**

The loss for the consolidated entity after providing for income tax amounted to \$3,202,825 (31 December 2024: \$2,449,088).

Prescient achieved significant operational and strategic progress during the reporting period, including completion of a Placement of \$2,978,500 to sophisticated and professional investors and Share Purchase Plan raising \$6,869,290 for a combined raise of \$9,847,790 (before costs). Funds were applied primarily to the continued development of the Company's first-in-class cancer therapy, PTX-100, including the ongoing Phase 2a clinical trial in relapsed/refractory Cutaneous T Cell Lymphoma (r/rCTCL).

#### **PTX-100**

##### **Phase 1b clinical trial**

Prescient completed data cleaning and a sub-analysis of the r/rCTCL cohort. Among seven evaluable patients, results demonstrated a 43% overall response rate and a 100% clinical benefit rate, with a mean duration of response of 12.4 months. No serious adverse events were attributed to PTX-100.

##### **Phase 2a clinical trial**

Progress continued with all six US clinical sites activated by December 2025, complementing three activated Australian sites. Five patients were dosed during the half-year, bringing total enrolment to six.

Engagement with European regulators resulted in European Medicines Agency (EMA) granting Orphan Drug Designation for PTX-100 in CTCL and the European Clinical Trials Information System (CTIS) granting authorisation for Prescient to initiate its PTX-100 clinical trial in patients with r/rCTCL in Europe. This follows earlier US Food and Drug Administration (FDA) Fast Track Designation for the treatment of adults with relapsed or refractory (r/r) mycosis fungoides.

Substantial Chemistry, Manufacturing, and Control (CMC) activities were undertaken to support the PTX-100 development plan. CMC capabilities have been substantially bolstered to conduct all necessary activities reflecting increased regulatory obligations associated with current and later-stage clinical studies.

#### **PTX-200**

The PTX-200 clinical trial in Acute Myeloid Leukaemia database underwent expert medical review to support preparation of the Clinical Study Report.

#### **CellPryme**

Prescient and collaborators at the Peter MacCallum Cancer Centre continued research demonstrating the potential impact of CellPryme A on the tumour microenvironment, supporting a manuscript submission proceeding through review. Outcomes of these studies may provide valuable insights into how CellPryme could overcome TME resistance and enhance the efficacy of other therapies in combination with CellPryme A.

### OmniCAR

OmniCAR variants previously demonstrated improved safety when unarmed, and potent tumour-killing activity when armed with binders in preclinical models. These developments preserve strategic optionality as sector conditions evolve.

### Corporate awareness and engagement

Prescient presented PTX-100 data at several industry and investor events, including AusBiotech Invest and BioMelbourne Network oncology forums, and continued engagement with potential partners for CellPryme M and OmniCAR.

### Significant changes in the state of affairs

During the half-year, the Company completed several capital raising and equity-related activities:

- On 4 August 2025, the Company issued 171,732,250 ordinary shares at \$0.04 per share having raised \$6,869,290 (before costs) in its Share Purchase Plan ("SPP") to existing investors.
- On 8 August 2025 and 27 August 2025, the Company issued 63,212,500 and 11,250,000 ordinary shares respectively to sophisticated and professional investors at \$0.04 per share under a Placement to raise \$2,978,500 (before costs).
- On 1 September 2025, the Company issued 12,309,738 unlisted options with an exercise price of \$0.06 per option and expiry date of 31 August 2029 to Reach Markets as part consideration for capital raising services.
- On 18 November 2025, the Company issued 12,942,721 unlisted options with an exercise price of \$0.10 per option and expiry date of 17 November 2029 to non-executive directors in accordance with shareholder approvals received at the 14 October 2025 Annual General Meeting.
- On 19 December 2025, the Company issued 21,780,000 unlisted options with an exercise price of \$0.10 (per option and expiry date of 17 November 2029 to employees under the Company's Executive Option Plan.

Other than these matters there were no further significant changes in the state of affairs during the half-year.

### Matters subsequent to the end of the half-year

In January 2026, the Company received an R&D Tax Incentive refund of \$4,356,397.

No other matter or circumstance has arisen since 31 December 2025 that has significantly affected or may significantly affect the operations or state of affairs of the consolidated entity.

### Auditor's independence declaration

A copy of the auditor's independence declaration as required under section 307C of the Corporations Act 2001 is set out immediately after this Directors' Report.

This report is made in accordance with a resolution of directors, pursuant to section 306(3)(a) of the Corporations Act 2001.

*Signed in accordance with a resolution of the Directors*



---

Dr James Campbell  
Non-Executive Chairman  
24 February 2026

For personal use only

## Lead Auditor's Independence Declaration under Section 307C of the Corporations Act 2001

### To the directors of Prescient Therapeutics Limited

As lead auditor for the review of Prescient Therapeutics Limited for the half-year ended 31 December 2025, I declare that, to the best of my knowledge and belief, there have been:

- no contraventions of the auditor independence requirements as set out in the *Corporations Act 2001* in relation to the review; and
- no contraventions of any applicable code of professional conduct in relation to the review.

This declaration is in respect of Prescient Therapeutics Limited and the entities it controlled during the period.

William Buck

**William Buck Audit (Vic) Pty Ltd**  
ABN 59 116 151 136

R. P. Burt

**R. P. Burt**  
Director

Melbourne, 24 February 2026

For personal use only

Prescient Therapeutics Limited  
Consolidated statement of profit or loss and other comprehensive income  
For the half-year ended 31 December 2025



		Consolidated	
	Note	31 December 2025 \$	31 December 2024 \$
Interest income		3,712	194,454
Other income	4	1,157,776	1,248,426
<b>Expenses</b>			
Research and development costs		(2,482,204)	(1,706,161)
Employment expenses		(1,529,157)	(1,478,202)
Corporate and administrative expenses		(722,431)	(648,591)
Share based payments	12	(406,577)	(27,234)
Interest expenses		(5,947)	(9,419)
Foreign exchange movements		(1,965)	(22,361)
<b>Loss before income tax expense</b>		(3,986,793)	(2,449,088)
Income tax expense		-	-
<b>Loss after income tax expense for the half-year attributable to the owners of Prescient Therapeutics Limited</b>		(3,986,793)	(2,449,088)
Other comprehensive income for the half-year, net of tax		-	-
<b>Total comprehensive income for the half-year attributable to the owners of Prescient Therapeutics Limited</b>		<u>(3,986,793)</u>	<u>(2,449,088)</u>
		<b>Cents</b>	<b>Cents</b>
Basic loss per share	11	(0.40)	(0.30)
Diluted loss per share	11	(0.40)	(0.30)

The above consolidated statement of profit or loss and other comprehensive income should be read in conjunction with the accompanying notes

For personal use only

Prescient Therapeutics Limited  
Consolidated statement of financial position  
As at 31 December 2025



	Consolidated	
	31 December	30 June 2025
Note	2025	2025
	\$	\$
<b>Assets</b>		
<b>Current assets</b>		
Cash and cash equivalents	9,747,630	6,906,804
Trade and other receivables	196,141	264,295
Amount due under loan funded share arrangement	-	293,404
Other financial assets	20,972	20,000
Prepayments	1,087,953	1,063,150
R&D tax incentive receivable	5,504,173	4,356,397
5	<u>16,556,869</u>	<u>12,904,050</u>
<b>Non-current assets</b>		
Property, plant and equipment	5,846	7,395
Right-of-use assets	268,227	-
Intangibles	1,650,176	1,650,176
Total non-current assets	<u>1,924,249</u>	<u>1,657,571</u>
<b>Total assets</b>	<u>18,481,118</u>	<u>14,561,621</u>
<b>Liabilities</b>		
<b>Current liabilities</b>		
Trade and other payables	1,132,677	3,093,570
Lease liabilities	49,944	-
Employee benefits	95,759	67,448
Total current liabilities	<u>1,278,380</u>	<u>3,161,018</u>
<b>Non-current liabilities</b>		
Lease liabilities	222,971	-
Employee benefits	8,175	13,431
Total non-current liabilities	<u>231,146</u>	<u>13,431</u>
<b>Total liabilities</b>	<u>1,509,526</u>	<u>3,174,449</u>
<b>Net assets</b>	<u>16,971,592</u>	<u>11,387,172</u>
<b>Equity</b>		
Issued capital	102,790,131	93,888,554
Reserves	1,714,106	1,565,658
Accumulated losses	(87,532,645)	(84,067,040)
6	<u>16,971,592</u>	<u>11,387,172</u>
<b>Total equity</b>	<u>16,971,592</u>	<u>11,387,172</u>

The above consolidated statement of financial position should be read in conjunction with the accompanying notes

**Prescient Therapeutics Limited**  
**Consolidated statement of changes in equity**  
**For the half-year ended 31 December 2025**



<b>Consolidated</b>	<b>Issued capital</b> \$	<b>Share based payments reserve</b> \$	<b>Share loan plan reserve</b> \$	<b>Accumulated losses</b> \$	<b>Total equity</b> \$
Balance at 1 July 2024	93,270,526	1,869,134	324,624	(77,396,996)	18,067,288
Loss after income tax expense for the half-year	-	-	-	(2,449,088)	(2,449,088)
Other comprehensive income for the half-year, net of tax	-	-	-	-	-
Total comprehensive income for the half-year	-	-	-	(2,449,088)	(2,449,088)
<i>Transactions with owners in their capacity as owners:</i>					
Vesting of Share-based payments	-	27,234	-	-	27,234
Lapse or expiry of unlisted share options	-	(537,942)	-	537,942	-
Balance at 31 December 2024	<u>93,270,526</u>	<u>1,358,426</u>	<u>324,624</u>	<u>(79,308,142)</u>	<u>15,645,434</u>

<b>Consolidated</b>	<b>Issued capital</b> \$	<b>Share based payments reserve</b> \$	<b>Share loan plan reserve</b> \$	<b>Accumulated losses</b> \$	<b>Total equity</b> \$
Balance at 1 July 2025	93,888,554	1,565,658	-	(84,067,040)	11,387,172
Loss after income tax expense for the half-year	-	-	-	(3,986,793)	(3,986,793)
Other comprehensive income for the half-year, net of tax	-	-	-	-	-
Total comprehensive income for the half-year	-	-	-	(3,986,793)	(3,986,793)
<i>Transactions with owners in their capacity as owners:</i>					
Shares issued from placement and share purchase plan (Note 6)	9,847,790	-	-	-	9,847,790
Transaction costs (Note 6)	(946,213)	263,059	-	-	(683,154)
Vesting of Share-based payments	-	406,577	-	-	406,577
Lapse or expiry of unlisted share options	-	(521,188)	-	521,188	-
Balance at 31 December 2025	<u>102,790,131</u>	<u>1,714,106</u>	<u>-</u>	<u>(87,532,645)</u>	<u>16,971,592</u>

The above consolidated statement of changes in equity should be read in conjunction with the accompanying notes

**Prescient Therapeutics Limited**  
**Consolidated statement of cash flows**  
**For the half-year ended 31 December 2025**



		<b>Consolidated</b>	
	<b>Note</b>	<b>31 December 2025</b>	<b>31 December 2024</b>
		<b>\$</b>	<b>\$</b>
<b>Cash flows used in operating activities</b>			
Payments to suppliers and employees (inclusive of GST)		(6,550,061)	(6,044,056)
Interest received		2,740	264,181
Interest paid		(5,947)	(9,419)
Other grants received		10,000	-
		<u>(6,543,268)</u>	<u>(5,789,294)</u>
Net cash used in operating activities			
<b>Cash flows from investing activities</b>			
Proceeds from release of term deposits		-	2,000,000
		<u>-</u>	<u>2,000,000</u>
Net cash from investing activities			
<b>Cash flows from financing activities</b>			
Proceeds from issue of shares	6	9,847,790	-
Transaction costs	6	(683,154)	-
Proceeds from loan funded shares		270,380	-
Repayment of borrowings		-	(296,211)
Repayment of lease liabilities		(48,957)	-
		<u>9,386,059</u>	<u>(296,211)</u>
Net cash from/ (used in) financing activities			
Net increase / (decrease) in cash and cash equivalents		2,842,791	(4,085,505)
Cash and cash equivalents at the beginning of the financial half-year		6,906,804	10,493,183
Effects of exchange rate changes on cash and cash equivalents		(1,965)	(22,361)
		<u>9,747,630</u>	<u>6,385,317</u>
Cash and cash equivalents at the end of the financial half-year			

*The above consolidated statement of cash flows should be read in conjunction with the accompanying notes*

For personal use only

**Note 1. General information**

The financial statements cover Prescient Therapeutics Limited (“Prescient” or “the Company”) and its controlled entities (“the consolidated entity”) for the half-year ended 31 December 2025. The financial statements are presented in Australian dollars, which is Prescient Therapeutics Limited’s functional and presentation currency.

Prescient Therapeutics Limited is a listed public company limited by shares, incorporated and domiciled in Australia. Its registered office and principal place of business is:

Suite 2, Level 11, 385 Bourke Street  
 Melbourne, VIC, 3000

A description of the nature of the consolidated entity’s operations and its principal activities are included in the Directors’ Report, which is not part of the financial statements.

The financial statements were authorised for issue, in accordance with a resolution of Directors, on 24 February 2026.

**Note 2. Material accounting policy information**

These general-purpose financial statements for the interim half-year reporting period ended 31 December 2025 have been prepared in accordance with Australian Accounting Standard *AASB 134 ‘Interim Financial Reporting’* and the *Corporations Act 2001*, as appropriate for for-profit oriented entities. Compliance with AASB 134 ensures compliance with International Financial Reporting Standard *IAS 34 ‘Interim Financial Reporting’*.

These general-purpose financial statements do not include all the notes of the type normally included in annual financial statements. Accordingly, these financial statements are to be read in conjunction with the annual report for the year ended 30 June 2025 and any public announcements made by the Consolidated entity during the interim reporting period in accordance with the continuous disclosure requirements of *the Corporations Act 2001*.

The principal accounting policies adopted are consistent with the most recent Annual Report for the year ended 30 June 2025.

**New or amended Accounting Standards and Interpretations adopted**

The consolidated entity has adopted all of the new or amended Accounting Standards and Interpretations issued by the Australian Accounting Standards Board (‘AASB’) that are mandatory for the current reporting period. The adoption of these Accounting Standards and Interpretations did not have any significant impact on the financial performance or position of the consolidated entity.

Any new or amended Accounting Standards or Interpretations that are not yet mandatory have not been early adopted.

**Note 3. Operating segments**

*Identification of reportable operating segments*

The Company operated predominately in the clinical stage oncology industry within Australia. AASB 8 requires operating segments to be identified on the basis of internal reports about the components of the Group that are regularly reviewed by the chief operating decision maker in order to allocate resources to the segment and to assess its performance. The Board reviews the Company as a whole in the business segment of clinical stage oncology within Australia.

**Note 4. Other income**

	<b>Consolidated</b>	
	<b>31 December 2025</b>	<b>31 December 2024</b>
	<b>\$</b>	<b>\$</b>
Government grants - Export Market Development Grant (EMDG)	10,000	-
R&D Tax Incentive	<u>1,147,776</u>	<u>1,248,426</u>
Other income	<u><u>1,157,776</u></u>	<u><u>1,248,426</u></u>

#### Note 4. Other income (continued)

The Research and Development ("R&D") Tax Incentive programme provides tax rebates and/ or offsets for expenditure on eligible R&D activities. Under the programme, Prescient, having expected aggregated annual turnover of under \$20 million, is eligible to a refundable R&D credit of 48.5% (31 December 2024: 48.5%) on eligible R&D expenditure incurred. A condition of eligibility is that the Company must ensure that more than 50% of total R&D activity costs will be incurred in Australia.

During the half-year ended 31 December 2025, the consolidated entity recognised R&D Tax Incentive other income of \$1,147,776 (31 December 2024: \$1,248,426).

#### Note 5. R&D Tax Incentive receivable

	Consolidated	
	31 December 2025	30 June 2025
	\$	\$
<i>Current assets</i>		
R&D Tax Incentive receivable	5,504,173	4,356,397

During the half-year ended 31 December 2025, the consolidated entity recognised R&D Tax Incentive other income of \$1,147,776. The R&D Tax Incentive receivable of \$4,356,397 as at 30 June 2025 was received after the balance date, on 21 January 2026.

#### Note 6. Issued capital

	Consolidated			
	31 December 2025	30 June 2025	31 December 2025	30 June 2025
	Shares	Shares	\$	\$
Ordinary shares - fully paid	1,051,514,543	805,319,793	102,790,131	93,888,554

#### Movements in ordinary share capital

Details	Date	Shares	\$ per share	\$
Balance	1 July 2025	805,319,793		93,888,554
Shares issued under Share Purchase Plan *	4 August 2025	171,732,250	0.04	6,869,290
Shares issued upon Placement	8 August 2025	63,212,500	0.04	2,528,500
Shares issued upon Placement	27 August 2025	11,250,000	0.04	450,000
Transaction costs				(946,213)
Balance	31 December 2025	1,051,514,543		102,790,131

#### Ordinary shares

Ordinary shares entitle the holder to participate in dividends and the proceeds on the winding up of the Company in proportion to the number of and amounts paid on the shares held. The fully paid ordinary shares have no par value and the Company does not have a limited amount of authorised capital.

\* 1,625,000 ordinary shares were issued to Directors of the Company which amounted to proceeds of \$65,000 as part of the Share Purchase Plan.

#### Note 7. Dividends

There were no dividends paid, recommended or declared during the current or previous financial half-year.

**Note 8. Contingent liabilities and commercial agreements that may impact future operations**

There were no new relevant agreements and there was no change to existing relevant agreements in the period 30 June 2025 to 31 December 2025. The consolidated entity has several agreements on foot whereby it is obliged to make industry standard royalty payments on future sales and future cash milestone payments if certain events occur. These agreements include the following:

**Yale University - PTX 100**

The agreement includes:

- Milestone payments based on dosing of patients in trials
- Milestone payments based on first New Drug Application (NDA) for a licensed product, and associated FDA approval
- Milestone payments based on market entry of licensed products in certain countries
- Royalty payments based on worldwide annual net sales

**University of Pennsylvania - OmniCAR**

The agreement includes:

- Development milestone payments based on first dosing of a subject in phases of clinical trials
- Milestone payments based on reaching certain levels of product net sales
- Royalties paid on levels of annual product net sales

**Oxford University - OmniCAR**

The agreement includes:

- Royalties paid on net sales of a licensed product
- Milestone payments based on commencement of phases and first regulatory approval of products

**Moffitt Cancer Center - CellPryme-A**

The agreement includes:

- Royalties paid on net sales of a licensed product
- Milestone payments based on commencement of phases and sales milestones of products

**Note 9. Commitments**

As at 31 December 2025, the Company had \$421,291 (US\$281,970) contractual commitments relating to research and development activities for PTX-100 (30 June 2025: nil).

The consolidated entity has entered into a number of licence agreements as outlined below. Under each of these agreements the Company is required to pay annual licence fees. There has been no change to licence agreements since 30 June 2025.

<b>Party to the Agreement</b>	<b>Intellectual property and technology associated with</b>
Yale University	PTX-100
University of Pennsylvania	OmniCAR
Oxford University	OmniCAR
Moffitt Cancer Center	CellPryme-A

**Note 10. Events after the reporting period**

On 21 January 2026, the Company received its R&D Tax Incentive refund of \$4,356,397 which was recorded as receivable at 30 June 2025.

No other matter or circumstance has arisen since 31 December 2025 that has significantly affected, or may significantly affect the operations or state of affairs of the consolidated entity.

**Note 11. Loss per share**

	<b>Consolidated</b>	
	<b>31 December 2025</b>	<b>31 December 2024</b>
	<b>\$</b>	<b>\$</b>
Loss after income tax attributable to the owners of Prescient Therapeutics Limited	<u>(3,986,793)</u>	<u>(2,449,088)</u>
	<b>Number</b>	<b>Number</b>
Weighted average number of ordinary shares used in calculating basic earnings per share	<u>1,002,977,813</u>	<u>805,319,793</u>
Weighted average number of ordinary shares used in calculating diluted earnings per share	<u>1,002,977,813</u>	<u>805,319,793</u>
	<b>Cents</b>	<b>Cents</b>
Basic loss per share	(0.40)	(0.30)
Diluted loss per share	(0.40)	(0.30)

The rights to options held by option holders have not been included in the weighted average number of ordinary shares for the purposes of calculating diluted EPS as they do not meet the requirements for inclusion in AASB 133 'Earnings Per Share'. The rights to options are non-dilutive as the consolidated entity is loss generating.

**Note 12. Share-based payments**

**Options**

On 1 September 2025, the Company issued 12,309,738 unlisted options with an exercise price of \$0.06 per option and an expiry date of 31 August 2029 to Reach Markets as part consideration as per mandate and as lead manager of the SPP and Placement. These options were fully vested and exercisable immediately. The fair value of the options on grant date was \$0.0214 per option and the share-based payment recognised in equity as transaction costs relating to options granted to lead manager was \$263,059 (31 December 2024: nil).

On 18 November 2025, the Company issued 12,942,721 unlisted options with an exercise price of \$0.10 per option and an expiry date of 17 November 2029 to Directors in accordance with shareholder approvals gained at the Annual General Meeting held 14 October 2025. 25% options vested immediately, 25% vest 12 months following the issue date, 25% vest 24 months following the issue date, and 25% vest 36 months following the issue date. The fair value of the options on grant date was \$0.0166 per option. The share-based payment recognised in the consolidated statement of profit or loss relating to options granted to Directors was \$85,664 (31 December 2024: \$16,514).

On 19 December 2025, the Company issued 21,780,000 unlisted options with an exercise price of \$0.10 per option and an expiry date of 17 November 2029 to employees under Executive Option Plan. 25% options vested immediately, 25% vest 12 months following the issue date, 25% vest 24 months following the issue date, and 25% vest 36 months following the issue date. The fair value of the options on grant date was \$0.0166 per option. The share-based payment recognised in the consolidated statement of profit or loss relating to options granted to the employees was \$320,913 (31 December 2024: \$10,720).

Set out below is a summary of options granted and on issue at the end of the half-year.

Note 12. Share-based payments (continued)

31 December 2025

Grant date	Expiry date	Exercise price	Balance at the start of the half-year	Granted	Exercised	Expired/ forfeited/ other	Balance at the end of the half-year
10/12/2020	08/12/2025	\$0.0968	3,000,000	-	-	(3,000,000)	-
31/05/2021	31/05/2026	\$0.3580	4,000,000	-	-	-	4,000,000
07/07/2021	07/07/2025	\$0.3630	1,950,000	-	-	(1,950,000)	-
09/07/2021	08/07/2025	\$0.3710	1,000,000	-	-	(1,000,000)	-
18/10/2021	17/10/2026	\$0.4120	200,000	-	-	-	200,000
21/10/2021	20/10/2026	\$0.4120	200,000	-	-	-	200,000
22/10/2021	21/10/2026	\$0.4120	200,000	-	-	-	200,000
29/10/2021	28/10/2026	\$0.4120	200,000	-	-	-	200,000
03/11/2021	02/11/2026	\$0.4120	200,000	-	-	-	200,000
11/05/2023	09/05/2027	\$0.1309	1,415,000	-	-	-	1,415,000
11/12/2024	11/12/2028	\$0.0621	1,415,000	-	-	-	1,415,000
20/01/2025	20/11/2030	\$0.0812	24,000,000	-	-	-	24,000,000
01/09/2025	31/08/2029	\$0.0600	-	12,309,738	-	-	12,309,738
15/10/2025	17/11/2029	\$0.1000	-	12,942,721	-	-	12,942,721
15/10/2025	17/11/2029	\$0.1000	-	21,780,000	-	-	21,780,000
			<u>37,780,000</u>	<u>47,032,459</u>	<u>-</u>	<u>(5,950,000)</u>	<u>78,862,459</u>
Weighted average exercise price			\$0.1438	\$0.0895	\$0.0000	\$0.2301	\$0.1049

For options granted during the reporting period, the Black-Scholes option pricing model was used to determine the fair value at grant date with the following valuation model inputs:

Grant date	Expiry date	Share price at grant date	Exercise price	Expected volatility	Dividend yield	Risk-free interest rate	Fair value at grant date
01/09/2025	31/08/2029	\$0.0400	\$0.0600	82.32%	-	3.50%	\$0.0214
15/10/2025	17/11/2029	\$0.0500	\$0.1000	79.93%	-	3.53%	\$0.0166

For personal use only

**Prescient Therapeutics Limited**  
**Directors' declaration**  
**31 December 2025**



In the Directors' opinion:

- the attached financial statements and notes comply with the Corporations Act 2001, Australian Accounting Standard AASB 134 'Interim Financial Reporting', the Corporations Regulations 2001 and other mandatory professional reporting requirements;
- the attached financial statements and notes give a true and fair view of the consolidated entity's financial position as at 31 December 2025 and of its performance for the financial half-year ended on that date; and
- there are reasonable grounds to believe that the Company will be able to pay its debts as and when they become due and payable.

Signed in accordance with a resolution of Directors

A handwritten signature in black ink, appearing to read "J Campbell", written over a horizontal line.

Dr James Campbell  
Non-Executive Chairman

24 February 2026

For personal use only

# Independent auditor's review report to the members of Prescient Therapeutics Limited

## Report on the half-year financial report



### Our conclusion

Based on our review, which is not an audit, we have not become aware of any matter that makes us believe that the accompanying half-year financial report of Prescient Therapeutics Limited (the Company), and its subsidiaries (the Group), does not comply with the *Corporations Act 2001*, including:

- giving a true and fair view of the Group's financial position as at 31 December 2025 and of its financial performance for the half-year then ended; and
- complying with Accounting Standard AASB 134 *Interim Financial Reporting* and the *Corporations Regulations 2001*.

### What was reviewed?

We have reviewed the accompanying half-year financial report of the Group, which comprises:

- the consolidated statement of financial position as at 31 December 2025,
- the consolidated statement of profit or loss and other comprehensive income for the half-year then ended,
- the consolidated statement of changes in equity for the half-year then ended,
- the consolidated statement of cash flows for the half-year then ended,
- notes to the financial statements, including material accounting policy information, and
- the directors' declaration.

### Basis for conclusion

We conducted our review in accordance with ASRE 2410 *Review of a Financial Report Performed by the Independent Auditor of the Entity*. Our responsibilities are further described in the *Auditor's responsibilities for the review of the financial report* section of our report. We are independent of the Group in accordance with the auditor independence requirements of the *Corporations Act 2001* and the ethical requirements of the Accounting Professional and Ethical Standards Board's APES 110 *Code of Ethics for Professional Accountants (including Independence Standards)* (the Code) that are relevant to our audit of the annual financial report in Australia. We have also fulfilled our other ethical responsibilities in accordance with the Code.

## Responsibilities of the directors for the financial report

The directors of the Group are responsible for the preparation of the half-year financial report that gives a true and fair view in accordance with Australian Accounting Standards and the *Corporations Act 2001* and for such internal control as the directors determine is necessary to enable the preparation of the half-year financial report that gives a true and fair view and is free from material misstatement, whether due to fraud or error.

## Auditor's responsibilities for the review of the financial report

Our responsibility is to express a conclusion on the half-year financial report based on our review. ASRE 2410 requires us to conclude whether we have become aware of any matter that makes us believe that the half-year financial report is not in accordance with the *Corporations Act 2001* including giving a true and fair view of the Group's financial position as at 31 December 2025 and its performance for the half-year ended on that date, and complying with Accounting Standard AASB 134 *Interim Financial Reporting* and the *Corporations Regulations 2001*.

A review of a half-year financial report consists of making enquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Australian Auditing Standards and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

William Buck

**William Buck Audit (Vic) Pty Ltd**  
ABN 59 116 151 136



**R. P. Burt**

Director

Melbourne, 24 February 2026

For personal use only